Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Purpose
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma.
Conditions
- Endometrial Serous Adenocarcinoma
- Uterine Corpus Carcinosarcoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Federation of Gynecology and Obstetrics (FIGO) 2009 stage IA-IVB, non-recurrent, chemotherapy (chemo)-naive, HER2-positive endometrial serous carcinoma or endometrial carcinosarcoma - Histologic confirmation of the original primary tumor is required. Submission of surgical pathology report (or endometrial biopsy pathology report in patients who never undergo hysterectomy) is required - Patients must be within 8 weeks of primary surgery (or endometrial biopsy in patients who never undergo hysterectomy) at the time of study registration - Patients may have measurable disease, non-measurable disease, or no measurable disease. In patients with measurable disease, lesions will be defined and monitored by RECIST v 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by computed tomography (CT) or magnetic resonance imaging (MRI). Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI - For patients with uterine-confined (stage I) disease, the tumor must be invasive into the myometrium. Any amount of myoinvasion is acceptable for eligibility. Patients with non-invasive disease, endometrial intraepithelial carcinoma alone, or disease confined to a polyp will be excluded - Additionally, patients must have the following histologic types to be eligible: - Serous adenocarcinoma (may include =< 10% non-serous histology) - Carcinosarcoma with serous epithelial component (only the serous component needs to be HER2 positive; may include =< 10% non-serous histology) - In cases where determination of serous is equivocal or challenging, aberrant p53 immunohistochemistry (IHC) (defined as overexpression of p53 compared to internal controls) will be sufficient for inclusion - All patients must have tumors that are HER2 positive as defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2018 Breast Cancer guidelines (https://documents.cap.org/documents/algorithim-evaluation-her2.pdf. In general HER2 positivity is defined as any of the following: - 3+ immunohistochemistry (IHC), - 2+ IHC with positive in situ hybridization (ISH) - Average HER2 copy number >= 6.0 signals/cell - Average HER2 copy number >= 4.0 and < 6.0 signals/cell, with concurrent IHC 3+ - HER2/CEP17 ratio >= 4.0 signals/cell - HER2/CEP 17 ratio >= 2.0 and < 4.0, with concurrent IHC 3+ IHC and ISH testing will be done locally, at each participating institution and interpreted by local pathologists. Alternatively, patients could be eligible if next generation sequencing (NGS) demonstrates HER2 (ERBB2) amplification. NGS testing can be performed through any designated labs as per the National Cancer Institute (NCI) MATCH/NCI Combo-MATCH trial (https://ecog-acrin.org/nci-match-eay131-designated-labs). Pathology report showing results of institutional HER2 testing (or NGS testing results) must be submitted. Sites must submit all results available (IHC, ISH, and NGS) - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 - Age >= 18 - Platelets >= 100,000/mcl (within 14 days prior to registration) - Absolute neutrophil count (ANC) >= 1,500/mcl (within 14 days prior to registration) - Creatinine =< 1.5 x institutional/laboratory upper limit of normal (ULN) or estimated Glomerular filtration rate (eGFR) >= 50 mL/min using either the Cockcroft-Gault equation, the Modification of Diet in Renal Disease Study, or as reported in the comprehensive metabolic panel/basic metabolic panel (eGFR). (within 14 days prior to registration) - Total serum bilirubin level =< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =< 3 x ULN may be enrolled) (within 14 days prior to registration) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (within 14 days prior to registration) - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial - Although the uterus will have been removed in the vast majority of patients, for patients of child-bearing potential: negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required. Patients will be considered of non-reproductive potential if they are either: - Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age, a high follicle stimulating hormone [FSH] level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR - Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion at least 6 weeks prior to registration - Have a congenital or acquired condition that prevents childbearing - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. NOTE: Patients with prior anthracycline exposure are NOT eligible - Patients with evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load - Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
Exclusion Criteria
- Prior Therapy: - Patients must NOT have received prior chemotherapy, biologic therapy, or targeted therapy for treatment of endometrial carcinoma - Patients must NOT have received prior radiation therapy for treatment of endometrial carcinoma. Prior radiation includes external beam pelvic radiation therapy, external beam extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy - NOTE: Vaginal brachytherapy for treatment of endometrial cancer is permitted during study treatment. Planned use of vaginal brachytherapy must be declared at time of registration - Patients may have received prior hormonal therapy for treatment of endometrial carcinoma. All hormonal therapy must be discontinued at least one week prior to registration - Patients may not have a planned interval cytoreduction or hysterectomy, prior to documentation of progression, after study registration - Patients may not have planned external beam radiotherapy, prior to documentation of progression, after study registration - Significant cardiovascular disease including: - Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg despite antihypertensive medications - Myocardial infarction or unstable angina within 6 months prior to registration - New York Heart Association functional classification II, III or IV - Serious cardiac arrhythmia requiring medication. This does not include asymptomatic, atrial fibrillation with controlled ventricular rate - Significant lung disease: dyspnea at rest grade 2 or greater (resulting from extensive tumor involvement or other causes), pneumonitis grade 2 or greater, interstitial lung disease grade 2 or greater, idiopathic pulmonary fibrosis, cystic fibrosis, Aspergillosis, active tuberculosis, or history of opportunistic infections (pneumocystis pneumonia or cytomegalovirus pneumonia) - Patients with uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), uncontrolled interstitial lung disease, symptomatic congestive heart failure, or psychiatric illness/social situations that would limit compliance with study requirements - Treatment with strong CYP2C8 or CYP3A4 inhibitors or inducers within 14 days or 5 drug-elimination half-lives, whichever is longer, prior to registration - Women who are unwilling to discontinue nursing
Study Design
- Phase
- Phase 2/Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Active Comparator Arm I (paclitaxel, carboplatin) |
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician. Patients undergo ECHO or MUGA scan at end of treatment and every 6 months for 2 years. |
|
Experimental Arm II (paclitaxel, carboplatin, Herceptin Hylecta) |
Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician. MAINTENANCE: Patients receive trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance therapy for up to 3 years from the start of treatment. Patients undergo ECHO or MUGA scan at end of treatment and every 6 months for 2 years. |
|
Experimental Arm III (paclitaxel, carboplatin, Phesgo) |
Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and pertuzumab/trastuzumab/hyaluronidase-zzxf SC over 5-8 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician. MAINTENANCE: Patients receive pertuzumab/trastuzumab/ hyaluronidase-zzxf SC over 5 minutes on day 1. Cycles repeat every 3 weeks for up to 1 year in absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance for up to 3 years from the start of treatment. Patients undergo ECHO or MUGA scan at end of treatment and every 6 months for 2 years. |
|
Recruiting Locations
Birmingham, Alabama 35233
Tucson, Arizona 85719
Tucson, Arizona 85719
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Auburn, California 95602
Concord, California 94520
Site Public Contact
925-674-2580
Duarte, California 91010
Huntington Beach, California 92648
Site Public Contact
877-467-3411
Irvine, California 92618
Site Public Contact
877-467-3411
Irvine, California 92618
Long Beach, California 90813
Site Public Contact
877-467-3411
Los Angeles, California 90027
Modesto, California 95355
Mountain View, California 94040
Riverside, California 92505
Roseville, California 95661
Sacramento, California 95817
Site Public Contact
916-734-3089
San Francisco, California 94115
Sunnyvale, California 94086
Upland, California 91786
Walnut Creek, California 94598
Site Public Contact
925-941-4246
Aurora, Colorado 80045
Site Public Contact
720-848-0650
Denver, Colorado 80206
Greeley, Colorado 80631
Highlands Ranch, Colorado 80129
Site Public Contact
720-848-0650
Danbury, Connecticut 06810
Site Public Contact
203-739-8074
Glastonbury, Connecticut 06033
Hartford, Connecticut 06105
New Haven, Connecticut 06520
Norwalk, Connecticut 06856
Waterbury, Connecticut 06708
Waterford, Connecticut 06385
Newark, Delaware 19713
Newark, Delaware 19713
Washington, District of Columbia 20016
Sarasota, Florida 34236
Site Public Contact
941-957-1000
Sarasota, Florida 34239
Site Public Contact
941-917-8383
Sarasota, Florida 34239
Site Public Contact
941-917-2225
Venice, Florida 34292
Atlanta, Georgia 30303
Site Public Contact
404-489-9164
Atlanta, Georgia 30308
Site Public Contact
888-946-7447
Atlanta, Georgia 30322
Site Public Contact
404-778-1868
Atlanta, Georgia 30342
Site Public Contact
404-851-7115
Augusta, Georgia 30912
Savannah, Georgia 31405
Honolulu, Hawaii 96813
Site Public Contact
808-545-8548
Honolulu, Hawaii 96826
Site Public Contact
808-983-6090
Boise, Idaho 83706
Boise, Idaho 83712
Caldwell, Idaho 83605
Coeur d'Alene, Idaho 83814
Fruitland, Idaho 83619
Meridian, Idaho 83642
Nampa, Idaho 83686
Nampa, Idaho 83687
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Twin Falls, Idaho 83301
Arlington Heights, Illinois 60005
Site Public Contact
847-618-4968
Aurora, Illinois 60504
Centralia, Illinois 62801
Chicago, Illinois 60611
Chicago, Illinois 60612
Site Public Contact
312-864-5204
Chicago, Illinois 60612
Chicago, Illinois 60637
Danville, Illinois 61832
Decatur, Illinois 62526
Decatur, Illinois 62526
DeKalb, Illinois 60115
Effingham, Illinois 62401
Effingham, Illinois 62401
Evanston, Illinois 60201
Site Public Contact
847-570-2109
Geneva, Illinois 60134
Glenview, Illinois 60026
Site Public Contact
847-570-2109
Highland Park, Illinois 60035
Site Public Contact
847-570-2109
Hinsdale, Illinois 60521
Site Public Contact
630-856-6757
Lake Forest, Illinois 60045
Mattoon, Illinois 61938
New Lenox, Illinois 60451
O'Fallon, Illinois 62269
Orland Park, Illinois 60462
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Urbana, Illinois 61801
Warrenville, Illinois 60555
Yorkville, Illinois 60560
Crown Point, Indiana 46307
Site Public Contact
219-310-2550
Dyer, Indiana 46311
Site Public Contact
219-924-8178
Goshen, Indiana 46526
Hobart, Indiana 46342
Site Public Contact
219-947-1795
Hobart, Indiana 46342
Indianapolis, Indiana 46202
Indianapolis, Indiana 46237
Site Public Contact
317-528-7060
Indianapolis, Indiana 46260
Indianapolis, Indiana 46312
Mooresville, Indiana 46158
Site Public Contact
317-834-3603
Munster, Indiana 46321
Site Public Contact
219-836-3349
Munster, Indiana 46321
South Bend, Indiana 46601
Site Public Contact
800-284-7370
Valparaiso, Indiana 46383
Ames, Iowa 50010
Site Public Contact
515-956-4132
Ames, Iowa 50010
Fort Dodge, Iowa 50501
Site Public Contact
515-956-4132
Iowa City, Iowa 52242
Site Public Contact
800-237-1225
Jefferson, Iowa 50129
Site Public Contact
515-956-4132
Marshalltown, Iowa 50158
Site Public Contact
515-956-4132
Edgewood, Kentucky 41017
Lexington, Kentucky 40503
Site Public Contact
859-260-6425
Louisville, Kentucky 40207
Baton Rouge, Louisiana 70805
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70817
Metairie, Louisiana 70006
New Orleans, Louisiana 70112
New Orleans, Louisiana 70115
New Orleans, Louisiana 70121
Scarborough, Maine 04074
Baltimore, Maryland 21204
Site Public Contact
443-849-3706
Baltimore, Maryland 21215
Baltimore, Maryland 21287
Bethesda, Maryland 20889-5600
Site Public Contact
301-319-2100
Westminster, Maryland 21157
Site Public Contact
410-871-6400
Springfield, Massachusetts 01199
Ann Arbor, Michigan 48109
Site Public Contact
800-865-1125
Battle Creek, Michigan 49017
Detroit, Michigan 48201
Farmington Hills, Michigan 48334
Farmington Hills, Michigan 48336
Site Public Contact
248-551-7695
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49009
Muskegon, Michigan 49444
Norton Shores, Michigan 49444
Reed City, Michigan 49677
Royal Oak, Michigan 48073
Site Public Contact
248-551-7695
Saint Joseph, Michigan 49085
Traverse City, Michigan 49684
Troy, Michigan 48085
Site Public Contact
248-551-7695
Wyoming, Michigan 49519
Coon Rapids, Minnesota 55433
Edina, Minnesota 55435
Maplewood, Minnesota 55109
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55455
Site Public Contact
612-624-2620
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55102
Columbia, Missouri 65212
Site Public Contact
573-882-7440
Rolla, Missouri 65401
Saint Louis, Missouri 63110
Saint Louis, Missouri 63141
Site Public Contact
314-251-7066
Springfield, Missouri 65807
Site Public Contact
417-269-4520
Anaconda, Montana 59711
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Kalispell, Montana 59901
Missoula, Montana 59802
Missoula, Montana 59804
Omaha, Nebraska 68114
Site Public Contact
402-354-5144
Omaha, Nebraska 68124
Las Vegas, Nevada 89102
Las Vegas, Nevada 89106
Las Vegas, Nevada 89148
Basking Ridge, New Jersey 07920
Site Public Contact
212-639-7592
Lakewood, New Jersey 08701
Livingston, New Jersey 07039
Long Branch, New Jersey 07740
Middletown, New Jersey 07748
Site Public Contact
212-639-7592
Montvale, New Jersey 07645
Site Public Contact
212-639-7592
Moorestown, New Jersey 08057
Site Public Contact
856-247-7395
New Brunswick, New Jersey 08903
Site Public Contact
732-235-7356
Somerville, New Jersey 08876
Voorhees, New Jersey 08043
Site Public Contact
856-247-7395
Albuquerque, New Mexico 87102
Albuquerque, New Mexico 87110
Rio Rancho, New Mexico 87124
Commack, New York 11725
Site Public Contact
212-639-7592
Harrison, New York 10604
Site Public Contact
212-639-7592
Mineola, New York 11501
New York, New York 10011
New York, New York 10016
New York, New York 10029
New York, New York 10065
Site Public Contact
212-639-7592
Rochester, New York 14642
Site Public Contact
585-275-5830
Syracuse, New York 13210
Site Public Contact
315-464-5476
Uniondale, New York 11553
Site Public Contact
212-639-7592
Cary, North Carolina 27518
Site Public Contact
919-781-7070
Chapel Hill, North Carolina 27599
Durham, North Carolina 27710
Site Public Contact
888-275-3853
Wilmington, North Carolina 28401
Site Public Contact
910-342-3000
Winston-Salem, North Carolina 27157
Site Public Contact
336-713-6771
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Beachwood, Ohio 44122
Belpre, Ohio 45714
Canton, Ohio 44710
Centerville, Ohio 45459
Chardon, Ohio 44024
Chillicothe, Ohio 45601
Cincinnati, Ohio 45220
Cleveland, Ohio 44106
Cleveland, Ohio 44109
Columbus, Ohio 43210
Columbus, Ohio 43213
Columbus, Ohio 43214
Columbus, Ohio 43219
Dayton, Ohio 45409
Grove City, Ohio 43123
Lancaster, Ohio 43130
Lima, Ohio 45801
Site Public Contact
419-226-9617
Marietta, Ohio 45750
Mentor, Ohio 44060
Mount Vernon, Ohio 43050
Newark, Ohio 43055
Perrysburg, Ohio 43551
Portsmouth, Ohio 45662
Springfield, Ohio 45504
Springfield, Ohio 45505
Sylvania, Ohio 43560
Toledo, Ohio 43608
Toledo, Ohio 43623
Westerville, Ohio 43081
Westlake, Ohio 44145
Zanesville, Ohio 43701
Oklahoma City, Oklahoma 73104
Tulsa, Oklahoma 74146
Site Public Contact
918-505-3200
Newberg, Oregon 97132
Ontario, Oregon 97914
Portland, Oregon 97210
Portland, Oregon 97213
Portland, Oregon 97225
Portland, Oregon 97239
Tualatin, Oregon 97062
Site Public Contact
503-413-1742
Bryn Mawr, Pennsylvania 19010
Erie, Pennsylvania 16544
Site Public Contact
814-452-5000
Jefferson Hills, Pennsylvania 15025
Media, Pennsylvania 19063
Monroeville, Pennsylvania 15146
Site Public Contact
412-858-7746
Paoli, Pennsylvania 19301
Philadelphia, Pennsylvania 19107
Site Public Contact
800-789-7366
Philadelphia, Pennsylvania 19107
Pittsburgh, Pennsylvania 15224
Site Public Contact
412-578-5000
West Chester, Pennsylvania 19380
Site Public Contact
610-431-5297
Wexford, Pennsylvania 15090
Willow Grove, Pennsylvania 19090
Wynnewood, Pennsylvania 19096
Providence, Rhode Island 02905
Site Public Contact
401-274-1122
Bluffton, South Carolina 29910
Aberdeen, South Dakota 57401
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57105
Sioux Falls, South Dakota 57117-5134
Germantown, Tennessee 38138
Austin, Texas 78701
Site Public Contact
512-324-7991
Dallas, Texas 75235
Dallas, Texas 75390
Houston, Texas 77030
Site Public Contact
713-790-2700
Houston, Texas 77070
Houston, Texas 77094
Site Public Contact
832-522-2873
Nassau Bay, Texas 77058
Sugar Land, Texas 77479
Site Public Contact
281-242-2873
The Woodlands, Texas 77385
Salt Lake City, Utah 84112
South Jordan, Utah 84009
Richmond, Virginia 23235
Richmond, Virginia 23298
Roanoke, Virginia 24016
Site Public Contact
540-985-8510
Edmonds, Washington 98026
Seattle, Washington 98122
Vancouver, Washington 98686
Site Public Contact
503-413-2150
Charleston, West Virginia 25304
Site Public Contact
304-388-9944
Morgantown, West Virginia 26506
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54303
La Crosse, Wisconsin 54601
Madison, Wisconsin 53792
Site Public Contact
800-622-8922
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
Mukwonago, Wisconsin 53149
New Richmond, Wisconsin 54017
Oconomowoc, Wisconsin 53066
Site Public Contact
262-928-7878
Oconto Falls, Wisconsin 54154
Sheboygan, Wisconsin 53081
Sturgeon Bay, Wisconsin 54235-1495
Waukesha, Wisconsin 53188
San Juan, Puerto Rico 00927
More Details
- NCT ID
- NCT05256225
- Status
- Recruiting
- Sponsor
- National Cancer Institute (NCI)
Detailed Description
PRIMARY OBJECTIVES: I. To evaluate the efficacy of trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) and pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) in combination with paclitaxel/carboplatin in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. (Phase II) II. To evaluate the efficacy of trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) and pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) in combination with paclitaxel/carboplatin in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. (Phase III) SECONDARY OBJECTIVES: I. To evaluate the overall response rate (ORR) in patients with measurable disease. II. To evaluate the duration of objective response in patients with measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. III. To determine the nature, frequency and degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 5.0 for each treatment arm. IV. To compare quality of life (QOL), as measured by Functional Assessment of Cancer Therapy - Endometrial Trial Outcome Index (FACT-En-TOI), in the experimental versus control arms. V. To compare patient-reported treatment-associated symptoms (diarrhea and rash) as measured with the Patient Reported Outcomes (PRO) - CTCAE, patient-reported fatigue as measured with the Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue short form, and other concerning side effects of treatment as measured by the item 'bothered by side effect', in the FACT-En TOI, respectively, in the experimental and control arms. VI. To assess the correlation of HER2 immunohistochemistry (IHC) expression and in situ hybridization (ISH) amplification with clinical outcome and response to HER2 targeted therapies. EXPLORATORY OBJECTIVE: I. To explore time to sustained deterioration in quality of life, as measured by a drop in the FACT-En-TOI by 6 or more points lasting for more than one PRO time point, in the experimental and control arms. OUTLINE: Patients are randomized to 1 of 3 arms. ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease (SD) or partial response (PR) who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician. ARM II: Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and trastuzumab/hyaluronidase-oysk subcutaneously (SC) over 2-5 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician. MAINTENANCE: Patients receive trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance therapy for up to 3 years from the start of treatment. ARM III: Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and pertuzumab/trastuzumab/hyaluronidase-zzxf SC over 5-8 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician. MAINTENANCE: Patients receive pertuzumab/trastuzumab/ hyaluronidase-zzxf SC over 5 minutes on day 1. Cycles repeat every 3 weeks for up to 1 year in absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance for up to 3 years from the start of treatment. Patients undergo echocardiogram (ECHO) or multigated acquisition scan (MUGA) scan at end of treatment and every 6 months for 2 years. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.